Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

Neelima V. Chu, Alice P.S. Kong, Dennis D. Kim, Debra Armstrong, Sunita Baxi, Reena Deutsch, Michael Caulfield, Sunder R. Mudaliar, Richard Reitz, Robert R. Henry, Peter D. Reaven

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

OBJECTIVE - Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel CVRF that occur largely as a result of insulin resistance and hyperinsulinemia. Therefore, we investigated whether diabetes medications that vary in their mechanism of action and ability to reduce insulin resistance may differ in their effects on both traditional and novel CVRF. RESEARCH DESIGN AND METHODS - We compared the addition of metformin or troglitazone therapy on CVRF in 22 subjects with type 2 diabetes who remained in poor glycemic control (with HbA1c >8.5%) while taking glyburide 10 mg twice daily. Subjects were initially randomized to either metformin 850 mg once daily or troglitazone 200 mg once daily. Both medications were then titrated upward as needed to achieve fasting plasma glucose <120 mg/dl. Measures of glucose control, insulin resistance, and CVRF (blood pressure, lipids, plasminogen activator inhibitor-1, C-reactive protein, fibrinogen, and small dense LDL) were assessed both before and after therapy. RESULTS - After 4 months of treatment, both metformin and troglitazone led to similar decreases in fasting plasma glucose and HbA1c. The reduction in insulin resistance determined by hyperinsulinemic-euglycemic clamp was nearly twofold greater with troglitazone than metformin. Metformin did not induce significant changes in blood pressure, LDL cholesterol, LDL size, HDL cholesterol, triglycerides, or plasminogen activator inhibitor-1. However, C-reactive protein did decrease by 33% (6 ± 1 to 4 ± 1 ng/l; P < 0.01). Troglitazone therapy was associated with increases in LDL size (26.21 ± 0.22 to 26.56 ± 0.25 nm; P = 0.04) and HDL cholesterol (33 ± 3 to 36 ± 3 mg/dl; P = 0.05) and decreases in triglycerides (197 ± 19 to 155 ± 23 mg/dl; P = 0.07) and C-reactive protein by 60% (8 ± 3 to 3 ± 1 ng/l, P < 0.01). CONCLUSIONS - For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy. These differences were not related to glycemic improvement but reflected, in part, the greater reduction in insulin resistance obtained with addition of troglitazone. These data suggest that medications that more effectively address this underlying metabolic defect may be more beneficial in reducing cardiovascular risk in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)542-549
Number of pages8
JournalDiabetes Care
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2002
Externally publishedYes

Fingerprint

troglitazone
Metformin
Type 2 Diabetes Mellitus
Insulin Resistance
C-Reactive Protein
Plasminogen Activator Inhibitor 1
Glucose
HDL Cholesterol
Fasting
Triglycerides
Therapeutics
Blood Pressure
Aptitude
Glucose Clamp Technique
Glyburide
Hyperinsulinism
LDL Cholesterol
Fibrinogen
Research Design
Cardiovascular Diseases

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. / Chu, Neelima V.; Kong, Alice P.S.; Kim, Dennis D.; Armstrong, Debra; Baxi, Sunita; Deutsch, Reena; Caulfield, Michael; Mudaliar, Sunder R.; Reitz, Richard; Henry, Robert R.; Reaven, Peter D.

In: Diabetes Care, Vol. 25, No. 3, 01.03.2002, p. 542-549.

Research output: Contribution to journalArticle

Chu, NV, Kong, APS, Kim, DD, Armstrong, D, Baxi, S, Deutsch, R, Caulfield, M, Mudaliar, SR, Reitz, R, Henry, RR & Reaven, PD 2002, 'Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes', Diabetes Care, vol. 25, no. 3, pp. 542-549. https://doi.org/10.2337/diacare.25.3.542
Chu, Neelima V. ; Kong, Alice P.S. ; Kim, Dennis D. ; Armstrong, Debra ; Baxi, Sunita ; Deutsch, Reena ; Caulfield, Michael ; Mudaliar, Sunder R. ; Reitz, Richard ; Henry, Robert R. ; Reaven, Peter D. / Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. In: Diabetes Care. 2002 ; Vol. 25, No. 3. pp. 542-549.
@article{80bed5c5aa054f18bf49da52cdfd9372,
title = "Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes",
abstract = "OBJECTIVE - Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel CVRF that occur largely as a result of insulin resistance and hyperinsulinemia. Therefore, we investigated whether diabetes medications that vary in their mechanism of action and ability to reduce insulin resistance may differ in their effects on both traditional and novel CVRF. RESEARCH DESIGN AND METHODS - We compared the addition of metformin or troglitazone therapy on CVRF in 22 subjects with type 2 diabetes who remained in poor glycemic control (with HbA1c >8.5{\%}) while taking glyburide 10 mg twice daily. Subjects were initially randomized to either metformin 850 mg once daily or troglitazone 200 mg once daily. Both medications were then titrated upward as needed to achieve fasting plasma glucose <120 mg/dl. Measures of glucose control, insulin resistance, and CVRF (blood pressure, lipids, plasminogen activator inhibitor-1, C-reactive protein, fibrinogen, and small dense LDL) were assessed both before and after therapy. RESULTS - After 4 months of treatment, both metformin and troglitazone led to similar decreases in fasting plasma glucose and HbA1c. The reduction in insulin resistance determined by hyperinsulinemic-euglycemic clamp was nearly twofold greater with troglitazone than metformin. Metformin did not induce significant changes in blood pressure, LDL cholesterol, LDL size, HDL cholesterol, triglycerides, or plasminogen activator inhibitor-1. However, C-reactive protein did decrease by 33{\%} (6 ± 1 to 4 ± 1 ng/l; P < 0.01). Troglitazone therapy was associated with increases in LDL size (26.21 ± 0.22 to 26.56 ± 0.25 nm; P = 0.04) and HDL cholesterol (33 ± 3 to 36 ± 3 mg/dl; P = 0.05) and decreases in triglycerides (197 ± 19 to 155 ± 23 mg/dl; P = 0.07) and C-reactive protein by 60{\%} (8 ± 3 to 3 ± 1 ng/l, P < 0.01). CONCLUSIONS - For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy. These differences were not related to glycemic improvement but reflected, in part, the greater reduction in insulin resistance obtained with addition of troglitazone. These data suggest that medications that more effectively address this underlying metabolic defect may be more beneficial in reducing cardiovascular risk in type 2 diabetes.",
author = "Chu, {Neelima V.} and Kong, {Alice P.S.} and Kim, {Dennis D.} and Debra Armstrong and Sunita Baxi and Reena Deutsch and Michael Caulfield and Mudaliar, {Sunder R.} and Richard Reitz and Henry, {Robert R.} and Reaven, {Peter D.}",
year = "2002",
month = "3",
day = "1",
doi = "10.2337/diacare.25.3.542",
language = "English (US)",
volume = "25",
pages = "542--549",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

AU - Chu, Neelima V.

AU - Kong, Alice P.S.

AU - Kim, Dennis D.

AU - Armstrong, Debra

AU - Baxi, Sunita

AU - Deutsch, Reena

AU - Caulfield, Michael

AU - Mudaliar, Sunder R.

AU - Reitz, Richard

AU - Henry, Robert R.

AU - Reaven, Peter D.

PY - 2002/3/1

Y1 - 2002/3/1

N2 - OBJECTIVE - Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel CVRF that occur largely as a result of insulin resistance and hyperinsulinemia. Therefore, we investigated whether diabetes medications that vary in their mechanism of action and ability to reduce insulin resistance may differ in their effects on both traditional and novel CVRF. RESEARCH DESIGN AND METHODS - We compared the addition of metformin or troglitazone therapy on CVRF in 22 subjects with type 2 diabetes who remained in poor glycemic control (with HbA1c >8.5%) while taking glyburide 10 mg twice daily. Subjects were initially randomized to either metformin 850 mg once daily or troglitazone 200 mg once daily. Both medications were then titrated upward as needed to achieve fasting plasma glucose <120 mg/dl. Measures of glucose control, insulin resistance, and CVRF (blood pressure, lipids, plasminogen activator inhibitor-1, C-reactive protein, fibrinogen, and small dense LDL) were assessed both before and after therapy. RESULTS - After 4 months of treatment, both metformin and troglitazone led to similar decreases in fasting plasma glucose and HbA1c. The reduction in insulin resistance determined by hyperinsulinemic-euglycemic clamp was nearly twofold greater with troglitazone than metformin. Metformin did not induce significant changes in blood pressure, LDL cholesterol, LDL size, HDL cholesterol, triglycerides, or plasminogen activator inhibitor-1. However, C-reactive protein did decrease by 33% (6 ± 1 to 4 ± 1 ng/l; P < 0.01). Troglitazone therapy was associated with increases in LDL size (26.21 ± 0.22 to 26.56 ± 0.25 nm; P = 0.04) and HDL cholesterol (33 ± 3 to 36 ± 3 mg/dl; P = 0.05) and decreases in triglycerides (197 ± 19 to 155 ± 23 mg/dl; P = 0.07) and C-reactive protein by 60% (8 ± 3 to 3 ± 1 ng/l, P < 0.01). CONCLUSIONS - For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy. These differences were not related to glycemic improvement but reflected, in part, the greater reduction in insulin resistance obtained with addition of troglitazone. These data suggest that medications that more effectively address this underlying metabolic defect may be more beneficial in reducing cardiovascular risk in type 2 diabetes.

AB - OBJECTIVE - Traditional cardiovascular risk factors (CVRF) only partly explain the excessive risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation for many novel CVRF that occur largely as a result of insulin resistance and hyperinsulinemia. Therefore, we investigated whether diabetes medications that vary in their mechanism of action and ability to reduce insulin resistance may differ in their effects on both traditional and novel CVRF. RESEARCH DESIGN AND METHODS - We compared the addition of metformin or troglitazone therapy on CVRF in 22 subjects with type 2 diabetes who remained in poor glycemic control (with HbA1c >8.5%) while taking glyburide 10 mg twice daily. Subjects were initially randomized to either metformin 850 mg once daily or troglitazone 200 mg once daily. Both medications were then titrated upward as needed to achieve fasting plasma glucose <120 mg/dl. Measures of glucose control, insulin resistance, and CVRF (blood pressure, lipids, plasminogen activator inhibitor-1, C-reactive protein, fibrinogen, and small dense LDL) were assessed both before and after therapy. RESULTS - After 4 months of treatment, both metformin and troglitazone led to similar decreases in fasting plasma glucose and HbA1c. The reduction in insulin resistance determined by hyperinsulinemic-euglycemic clamp was nearly twofold greater with troglitazone than metformin. Metformin did not induce significant changes in blood pressure, LDL cholesterol, LDL size, HDL cholesterol, triglycerides, or plasminogen activator inhibitor-1. However, C-reactive protein did decrease by 33% (6 ± 1 to 4 ± 1 ng/l; P < 0.01). Troglitazone therapy was associated with increases in LDL size (26.21 ± 0.22 to 26.56 ± 0.25 nm; P = 0.04) and HDL cholesterol (33 ± 3 to 36 ± 3 mg/dl; P = 0.05) and decreases in triglycerides (197 ± 19 to 155 ± 23 mg/dl; P = 0.07) and C-reactive protein by 60% (8 ± 3 to 3 ± 1 ng/l, P < 0.01). CONCLUSIONS - For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy. These differences were not related to glycemic improvement but reflected, in part, the greater reduction in insulin resistance obtained with addition of troglitazone. These data suggest that medications that more effectively address this underlying metabolic defect may be more beneficial in reducing cardiovascular risk in type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036517747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036517747&partnerID=8YFLogxK

U2 - 10.2337/diacare.25.3.542

DO - 10.2337/diacare.25.3.542

M3 - Article

C2 - 11874944

AN - SCOPUS:0036517747

VL - 25

SP - 542

EP - 549

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -